MAP2K7 and non-small cell lung carcinoma: KRAS mutations are present in 30% of lung adenocarcinomas and lead to activation of the Ras-Raf-MEK-ERK signaling pathway, making it an attractive target for small molecule inhibition in KRAS mutant NSCLC [32].